Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions (NEVO RES-I)

This study has been terminated.
(The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3 years. This decision took the absence of safety signals into account.)
Sponsor:
Collaborator:
Conor Medsystems
Information provided by (Responsible Party):
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00606333
First received: January 17, 2008
Last updated: October 24, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries. The study will evaluate the outcomes of a new drug-eluting stent compared to an approved drug-eluting stent.

While Cordis made a business decision to no longer pursue NEVO™ development and commercialization, the patients will be followed up as per protocol. This includes performing all protocol required follow-up visits and the collection and reporting of all safety information.


Condition Intervention
Coronary Atherosclerosis
Device: NEVO™ Sirolimus-eluting Coronary Stent System
Device: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions

Resource links provided by NLM:


Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • Angiographic endpoint of in-stent late lumen loss as measured by QCA. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Target Lesion Failure defined as cardiac death that cannot be clearly attributed to a non-cardiac event or non-target vessel, target vessel related myocardial infarction or clinically driven target lesion revascularization. [ Time Frame: hospital discharge, 30 days, 6 months and annually through five years. ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure defined as any myocardial infarction or cardiac death that cannot be attributed to a non-target vessel or any target vessel revascularization. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  • Major Adverse Cardiac Events defined as an adjudicated composite of death, emergent coronary artery bypass graft surgery, target lesion revascularization, or new myocardial infarction. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  • Incidence of stent thrombosis [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  • Incidence of target lesion revascularization and target vessel revascularization. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  • Device Success [ Time Frame: Procedural ] [ Designated as safety issue: No ]
  • Lesion success [ Time Frame: Procedural ] [ Designated as safety issue: No ]
  • Procedure Success [ Time Frame: Hospital Discharge ] [ Designated as safety issue: Yes ]
  • Angiographic in-stent and in-segment binary restenosis. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • In-stent minimum lumen diameter [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Percent volume obstruction of the stent by intravascular ultrasound evaluation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Patient reported outcomes as measured by three standardized quality of life surveys. [ Time Frame: Baseline, 30 days, 6 months and 12 months ] [ Designated as safety issue: No ]

Enrollment: 394
Study Start Date: March 2008
Study Completion Date: October 2012
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Investigational arm
Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
Device: NEVO™ Sirolimus-eluting Coronary Stent System
Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Active Comparator: Control Arm
Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
Device: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Other Name: Taxus Liberte Paclitaxel-eluting Coronary Stent System

Detailed Description:

Restenosis remains a frequent cause of late failure following successful coronary angioplasty occurring in an estimated 20-40% of procedures performed. Coronary stents provide mechanical scaffolding that helps reduce restenosis by limiting the extent of elastic recoil and late vascular remodeling. Despite improvements over balloon angioplasty alone, restenosis following coronary stenting procedures has been cited to occur in 20-40% of cases and is primarily a result of neointimal hyperplasia. Thus, stents which are capable of delivering drugs to limit neointimal hyperplasia, in addition to providing mechanical support at the area of the lesion, have been developed to further limit the extent of restenosis following coronary stenting. There are several pharmacologic agents approved for use with drug-eluting stents.Two drugs have been widely studied in controlled clinical trials and real-world patient populations, sirolimus and paclitaxel.

This study will evaluate a new sirolimus-eluting cobalt chromium coronary stent system compared to an approved paclitaxel-eluting coronary stent system in the treatment of single de novo coronary lesions in native coronary arteries. Subjects meeting qualification will be randomized in a 1:1 fashion to treatment with the Conor sirolimus-eluting coronary stent or to treatment with an approved paclitaxel-eluting coronary stent. All subjects will undergo angiographic follow-up at six months and complete clinical follow-up for a period of five years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Eligible for percutaneous coronary intervention and coronary artery bypass graft surgery.
  • Diagnosis of stable or unstable angina or silent ischemia
  • Left ventricular ejection fraction >30%
  • The subject requires treatment of a single de novo lesion in a native coronary artery.
  • Lesion to be treated is less than or equal to 28 mm in length in a vessel that is 2.5-3.5mm diameter.
  • The target lesion diameter stenosis is >50% and <100% by visual estimate.
  • The target lesion is a minimum of 10 mm distance from any previously treated segment of the target vessel.
  • The subject understands the study requirements, is willing to comply with all study procedures and has provided written informed consent.

Exclusion Criteria:

  • The subject has undergone coronary revascularization to any vessel within 30 days.
  • The subject has undergone target vessel revascularization within 6 months.
  • Treatment of more than one qualifying lesion is required at the time of enrollment, or is planned within 30 days following enrollment.
  • The subject has known sensitivity to sirolimus, paclitaxel, the polymeric matrices, stainless steel or cobalt chromium.
  • There is planned treatment of the target lesion with any device other than the pre-dilatation balloon angioplasty catheter.
  • The subject had a myocardial infarction within 72 hours, or presents with CK elevation > 2 times upper limit normal associated with elevated CK-MB.
  • The subject is in cardiogenic shock.
  • The subject had a cerebrovascular accident within the past 6 months.
  • The subject has acute or chronic renal dysfunction (defined as creatinine >2.0 mg/dl).
  • The subject has a contraindication to aspirin or clopidogrel.
  • The subject has thrombocytopenia (platelet count < 100,000/mm3.
  • The subject has had active gastrointestinal bleeding within the past 3 months.
  • The subject has a known bleeding or hypercoagulable disorder.
  • The subject has had prior anaphylactoid reaction to contrast agents or has contrast sensitivity that cannot be controlled with pre-medication.
  • The subject is currently taking immunosuppressant therapy.
  • The subject is currently, or has been treated wtih either Rapamune or paclitaxel within 12 months of the procedure.
  • The subject is a female with a positive pregnancy test or is lactating.
  • The subject has an active infection.
  • The subject has co-morbidities that could interfere wtih completion of study procedures, or life expectancy less than 24 months.
  • The subject is participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study.

Angiographic Exclusion Criteria

  • Left main disease >50% diameter stenosis.
  • The target lesion is ostial.
  • The target lesion or target vessel are severely calcified.
  • The target lesion involves a bifurcation with diseased branch vessel greater than or equal to 2.0 mm that would require intervention or protection.
  • The target lesion has TIMI o or TIMI I flow.
  • Angiographic evidence of thrombus.
  • The target vessel has had prior stent placement.
  • The patient has had prior coronary brachytherapy.
  • There is angiographic restenosis of any previously treated segment of the target vessel, or atherosclerotic area wtih >50% diameter stenosis outside of the target lesion.
  • The subject has undergone prior CABG.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00606333

Locations
Brazil
Instituto Dante Pazzanese de Cardiologia
Sao Paulo, Brazil, 04012-909
New Zealand
Mercy Angiography Unit
Epsom, Auckland, New Zealand
Sponsors and Collaborators
Cordis Corporation
Conor Medsystems
Investigators
Principal Investigator: John Ormiston, MB ChM Mercy Angiography Unit
Principal Investigator: Alexandre Abizaid, MD. PhD Instituto Dante Pazzanese de Cardiologia
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cordis Corporation
ClinicalTrials.gov Identifier: NCT00606333     History of Changes
Other Study ID Numbers: CP-06
Study First Received: January 17, 2008
Last Updated: October 24, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Committee of Ethics in Research
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: German Institute of Medical Documentation and Information
Netherlands: Dutch Health Care Inspectorate
New Zealand: Institutional Review Board
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Cordis Corporation:
Coronary artery disease
drug-eluting stents
sirolimus-eluting coronary stents

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Coronary Artery Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Sirolimus
Everolimus
Paclitaxel
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014